Cocaine use disorder affects an estimated 21 million people globally, yet no FDA-approved pharmacotherapy currently exists for it. Ibogaine — a psychoactive alkaloid derived from the Tabernanthe iboga plant — has attracted growing interest as a potential treatment, primarily because of case reports and observational data suggesting it may interrupt stimulant cravings and support detoxification in ways that conventional approaches cannot. Research remains early-stage, and most evidence comes from observational studies and preclinical work rather than randomized controlled trials.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

What the Research Shows

Direct clinical trial evidence for ibogaine in cocaine use disorder is limited. No large-scale randomized controlled trial has been completed specifically targeting cocaine dependence. However, several lines of evidence inform what we currently know:

Observational and Retrospective Data

Brown TK and Alper (2018), published in the American Journal of Drug and Alcohol Abuse, conducted a prospective study of 30 opioid-dependent patients treated with ibogaine. While primarily focused on opioids, a meaningful subset of participants also reported concurrent stimulant use, providing limited but suggestive signals that ibogaine may reduce stimulant cravings alongside opioid withdrawal. The authors noted that self-reported craving reductions extended beyond opioids for some participants, though cocaine-specific outcomes were not the primary endpoint.

Preclinical Evidence

Much of what researchers understand about ibogaine's effect on cocaine comes from animal studies. Glick SD and colleagues conducted multiple preclinical studies in rodent addiction models demonstrating that ibogaine and its synthetic analog 18-MC (18-methoxycoronaridine) significantly reduced self-administration of cocaine in rats. These studies showed dose-dependent decreases in cocaine-seeking behavior, providing a neurobiological rationale for human research. Critically, 18-MC appeared to produce these effects with a more favorable safety profile than ibogaine itself, which has driven interest in developing it as a clinical candidate.

Case Reports and Clinical Observations

Multiple published case reports and clinical observations from ibogaine treatment centers — particularly in Mexico, the Netherlands, and other jurisdictions where it operates legally or in regulatory gray zones — describe patients with cocaine use disorder reporting significant reductions in cravings and use following a single ibogaine session. These accounts are consistent in theme but cannot establish causality, control for placebo effects, or account for selection bias. They remain hypothesis-generating rather than confirmatory.

Mixed-Substance Studies

Noller GE et al. (2018), published in Substance Abuse and Rehabilitation, conducted a prospective observational pilot study in New Zealand (N=14) examining ibogaine for opioid dependence. Ibogaine is a Class A controlled substance in New Zealand under the Misuse of Drugs Act 1975, and the study was conducted under special Ministry of Health approval rather than in a permissive regulatory environment. While this study did not specifically target cocaine, it demonstrated that ibogaine could be administered in a supervised clinical setting to patients with opioid use disorders, with participants reporting reductions in both drug use and cravings at follow-up. The small sample and lack of control group limit conclusions, but it supports the feasibility of studying ibogaine in substance-dependent populations more broadly.

Clinical Trial Results

The table below reflects published studies with data relevant to cocaine or stimulant use disorder. Note that no phase 2 or phase 3 randomized controlled trial specific to cocaine has been completed as of 2026.

Trial / Study Phase / Design N Key Outcome Year
Brown TK & Alper (prospective study) Prospective observational 30 (primarily opioid; stimulant use noted) Reductions in self-reported drug cravings including stimulants; cocaine-specific outcomes not primary endpoint 2018
Noller GE et al. (New Zealand pilot) Prospective observational pilot 14 (opioid dependence) Reduced drug use and cravings at follow-up; feasibility signal for supervised ibogaine administration under special regulatory approval 2018
Glick SD et al. (18-MC rodent models) Preclinical (rodent) Multiple cohorts Dose-dependent reduction in cocaine self-administration; 18-MC showed favorable safety vs. ibogaine Various

📋 Research gap: No completed phase 2 or phase 3 randomized controlled trial has specifically evaluated ibogaine for cocaine use disorder in humans. All human evidence to date is observational or from mixed-substance studies.

How Ibogaine May Help With Cocaine Addiction

Cocaine addiction is driven primarily by dysregulation of the dopamine reward system. Cocaine blocks the dopamine transporter (DAT), flooding the nucleus accumbens with dopamine and producing intense euphoria — and, over time, a profound dopamine deficit during abstinence that drives compulsive seeking. Ibogaine's hypothesized mechanisms in this context include:

Dopamine System Reset

Ibogaine and its active metabolite noribogaine interact with the dopamine transporter and modulate dopaminergic signaling in the mesolimbic pathway. Preclinical evidence suggests ibogaine may help normalize dopamine receptor sensitivity that becomes blunted after chronic cocaine exposure, potentially reducing the anhedonia and intense craving that characterize early cocaine abstinence.

Sigma-2 Receptor Activity

Ibogaine has affinity for sigma-2 receptors, which are implicated in the modulation of dopamine and cocaine's rewarding effects. This interaction may contribute to the anti-addictive properties observed in preclinical models, though the precise role of this mechanism in humans has not been established.

GDNF Upregulation

Animal studies suggest ibogaine increases expression of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA) — a brain region central to reward processing. GDNF upregulation has been associated with reduced dopamine neuron sensitivity to cocaine in rodent models, suggesting a potential neurorestorative mechanism that could support long-term abstinence.

Serotonergic and Psychological Effects

Ibogaine's serotonergic activity, particularly its agonism at 5-HT2A receptors, produces a prolonged visionary and introspective state lasting 12–36 hours. Many patients and clinicians report that this experience facilitates psychological insight into addiction-related patterns, emotional trauma, and motivation for change. While this is difficult to quantify in clinical trials, it may represent an important component of therapeutic effect — particularly for cocaine use disorder, which has a strong psychological and behavioral reinforcement component.

NMDA Receptor Antagonism

Ibogaine acts as an open-channel NMDA receptor antagonist, similar in some ways to ketamine. This action may reduce the neuroplastic changes — sometimes called "synaptic tagging" — that encode drug-associated memories and cues, potentially weakening the conditioned responses that trigger relapse in cocaine-dependent individuals.

Limitations and What We Don't Know Yet

Honest appraisal of the evidence requires acknowledging significant gaps:

  • No cocaine-specific RCT: The fundamental limitation is that no randomized, placebo-controlled trial has tested ibogaine specifically for cocaine use disorder in humans. All positive signals come from observational data, case reports, or animal models — none of which can establish efficacy.
  • Selection bias in observational data: People who travel to ibogaine clinics (often at considerable expense) are highly motivated for change, may have tried many prior treatments, and are self-selected. These factors confound outcome interpretation.
  • Short follow-up: Most observational reports measure outcomes at one to three months. Long-term relapse rates — which are the clinically meaningful metric for cocaine use disorder — are largely unknown for ibogaine-treated populations.
  • Optimal dosing unknown: Unlike opioid applications where some dosing protocols have been studied, there is no evidence-based dosing protocol for cocaine use disorder specifically.
  • Polydrug complexity: Most real-world ibogaine candidates have co-occurring alcohol, opioid, or other substance use, making it difficult to isolate ibogaine's effect on cocaine specifically.
  • Mechanism not fully characterized: While preclinical work implicates dopamine, GDNF, and sigma receptors, the precise mechanisms responsible for any anti-cocaine effect in humans remain speculative.
  • No FDA-approved comparator: Paradoxically, the absence of any approved pharmacotherapy for cocaine makes it harder to contextualize ibogaine's effect size, but also makes the unmet need argument stronger for continued research.

Safety Considerations

Cocaine use disorder introduces specific safety considerations that must be weighed alongside ibogaine's known risks:

Cardiac Risk Amplification

Both cocaine and ibogaine independently carry cardiac risks. Cocaine causes coronary vasospasm, arrhythmias, and QTc interval changes. Ibogaine prolongs the QTc interval and carries risk of fatal ventricular arrhythmias. Combining these risks — or administering ibogaine to someone with cocaine-damaged cardiac tissue — meaningfully increases the risk of serious adverse events. Cardiac screening including ECG, echocardiogram, and electrolyte panel is essential before any ibogaine treatment in this population.

Acute Cocaine Use Before Treatment

Cocaine use in the hours or days before ibogaine administration may leave residual cardiovascular effects (elevated heart rate, elevated blood pressure, coronary vasospasm risk) that compound ibogaine's arrhythmia potential. Most responsible clinical protocols require a verifiable period of cocaine abstinence — typically at least 24–72 hours, and ideally longer — before ibogaine administration.

Stimulant-Related Psychosis Risk

Chronic cocaine use is associated with stimulant-induced psychosis and persistent paranoia in some individuals. Ibogaine's intense psychedelic effects — lasting up to 36 hours — may be harder to manage in patients with a history of stimulant psychosis. Pre-treatment psychiatric evaluation is strongly recommended.

Known Fatalities

Ibogaine-related deaths have been documented in the literature. Many involve unscreened patients, concurrent substance use, or inadequate medical monitoring. The risk is not theoretical. In the Williams et al. (2023) study in veterans — which used magnesium pre-treatment to stabilize cardiac rhythm — one serious adverse event involving QTc prolongation was recorded even in a screened, medically supervised population.

Electrolyte Management

Hypomagnesemia and hypokalemia, which lower the threshold for ventricular arrhythmia, are common in people with substance use disorders. Electrolyte correction before ibogaine administration is a minimum standard of care in responsible clinical settings.

Current Treatment Landscape

Cocaine use disorder remains one of the most treatment-resistant addictions because, unlike opioid or alcohol use disorder, it has no FDA-approved pharmacotherapy. Current standard-of-care approaches rely almost entirely on behavioral and psychosocial interventions:

  • Cognitive Behavioral Therapy (CBT): The most evidence-supported intervention; helps patients recognize and manage triggers and cravings.
  • Contingency Management: Uses voucher-based incentives to reinforce abstinence; one of the most effective behavioral approaches available.
  • 12-Step and peer support programs: Widely used; evidence for long-term abstinence is mixed but community support is valued by many in recovery.
  • Off-label pharmacotherapy: No medications are approved, but drugs including modafinil, topiramate, disulfiram, and N-acetylcysteine have been studied with inconsistent results. None have achieved regulatory approval.
  • Emerging psychedelic-assisted treatments: Beyond ibogaine, psilocybin and MDMA-assisted therapies are under investigation for various substance use disorders, though cocaine-specific trials remain limited.

Given the near-total absence of approved pharmacological options, ibogaine occupies a distinctive niche: it is the only compound with both a plausible neurobiological mechanism (dopamine system modulation, GDNF upregulation) and real-world observational data suggesting reduction in cocaine use. This creates a genuine scientific and ethical rationale for well-designed trials, even as the current evidence base remains insufficient to recommend it as a standard treatment.

Several research groups are currently pursuing ibogaine analogs — particularly 18-MC and tabernanthalog — that aim to preserve anti-addictive effects while eliminating or reducing cardiac and hallucinogenic risks. These compounds may eventually offer a safer pathway to exploit ibogaine's mechanism in cocaine and other stimulant use disorders.

Frequently Asked Questions

No completed phase 2 or phase 3 randomized controlled trial has specifically evaluated ibogaine for cocaine use disorder. The available human evidence consists of observational studies, retrospective analyses, and case reports — none of which can establish efficacy. Preclinical rodent studies show promising reductions in cocaine self-administration, particularly with the ibogaine analog 18-MC, but animal findings do not automatically translate to humans. Research is ongoing, and the evidence base may grow in coming years.
Ibogaine is thought to act on several systems relevant to cocaine addiction: it modulates dopamine transporter activity, potentially helping normalize the dopamine deficit that drives cravings during abstinence; it upregulates GDNF in the ventral tegmental area, which may reduce reward neuron sensitivity to cocaine; it acts as an NMDA receptor antagonist, potentially weakening drug-cue associations; and it engages sigma-2 receptors, which are implicated in cocaine's rewarding effects. Its serotonergic activity also produces a prolonged introspective state that some patients report as psychologically transformative. These mechanisms are plausible but not definitively proven in human cocaine users.
Potentially more risky in several ways. Both cocaine and ibogaine independently affect cardiac rhythm — cocaine through coronary vasospasm and catecholamine surges, ibogaine through QTc prolongation. Combining these risks, or administering ibogaine to someone whose heart has been stressed by chronic cocaine use, amplifies the arrhythmia risk. Additionally, cocaine use in the days before treatment may leave cardiovascular residual effects. Responsible clinical protocols require cardiac screening, electrolyte correction, and a cocaine-free period before ibogaine administration. A history of cocaine-induced psychosis also raises additional psychiatric screening requirements.
Polydrug use is common in real-world ibogaine settings, and observational data — including the Brown & Alper (2018) prospective study and the Noller et al. (2018) New Zealand pilot — include patients with mixed substance use histories. Ibogaine has the most established observational evidence for opioid use disorder, and some patients with concurrent cocaine use have been treated. However, polysubstance use increases both the complexity of treatment and the safety risk profile. Each substance adds potential drug interactions, cardiac concerns, and psychological variables. Thorough pre-treatment assessment is essential, and responsible programs typically require medical clearance for all substances present.
Ibogaine is a Schedule I controlled substance in the United States, making it illegal to administer there outside of approved research. Treatment centers operating legally or in regulatory gray zones exist in countries including Mexico, the Netherlands, Portugal, South Africa, and others. The quality and medical standards of these facilities vary enormously — some have robust cardiac monitoring and physician oversight, others do not. Anyone considering ibogaine for cocaine use disorder should research facilities carefully, verify medical screening protocols, and consult with an addiction medicine physician before traveling abroad for treatment.
18-MC (18-methoxycoronaridine), studied extensively by Glick SD and colleagues in preclinical rodent models, reduces cocaine self-administration while appearing to carry a more favorable cardiac and psychedelic side-effect profile than ibogaine itself. This has generated significant scientific interest in 18-MC and related analogs like tabernanthalog as potential clinical candidates. However, 18-MC has not yet completed human clinical trials for cocaine use disorder. It remains an investigational compound. The hope is that analogs could eventually deliver ibogaine's anti-addictive benefits with reduced risk — but this remains to be demonstrated in human studies.
There are currently no FDA-approved medications for cocaine use disorder — a significant unmet need. Standard care relies on behavioral therapies like CBT and contingency management, which are effective for many but leave a substantial proportion of patients without lasting relief. Ibogaine cannot yet be compared head-to-head with these approaches because no controlled trial has been done, but its proposed pharmacological mechanism — directly targeting the dopamine dysregulation that drives cocaine addiction — is distinct from any existing behavioral intervention. This mechanistic uniqueness, combined with the absence of approved alternatives, is a key argument for investing in rigorous ibogaine research for cocaine use disorder.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.